Skip to main content
Premium Trial:

Request an Annual Quote

DiaDexus Licenses TRAIL Proteins to Human Genome Sciences

NEW YORK, Oct.16 (GenomeWeb News) - Human Genome Sciences has acquired from DiaDexus exclusive, worldwide rights to develop and commercialize diagnostic immunohistochemical tests based on the company's TRAIL Receptor-1 and TRAIL Receptor-2 proteins

DiaDexus retains exclusive commercial rights for diagnostics based on TRAIL-R1 and TRAIL-R2 in other formats, the firm said. Terms of the deal call for DiaDexus to receive an upfront payment, clinical and commercial milestone payments, and royalties.

Human Genome Sciences originally discovered the TRAIL Receptor-1 and TRAIL Receptor-2 proteins. DiaDexus acquired diagnostic rights to them through an agreement with GlaxoSmithKline.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.